Enhabit Plans for ‘Aggressive’ Hospice Growth

Why It Matters

The plan positions Enhabit to capture higher‑margin hospice growth while leveraging private‑equity capital, reshaping competitive dynamics in the post‑acute care market. Success could signal a new benchmark for consolidation and profitability in a sector facing staffing and regulatory pressures.

Key Takeaways

• Enhabit targets double‑digit growth under new CEO Dale Clift
• Private‑equity deal valued at $1.1 billion took Enhabit private
• 117 hospice sites and 249 home‑health locations span 34 states
• Q4 adjusted EBITDA $28 million, up 3.7% sequentially
• CEO plans to prioritize hospice growth over home‑health expansion

Pulse Analysis

Enhabit Inc., a Texas‑based provider of hospice and home‑health services, completed a $1.1 billion leveraged buyout by Kinderhook Industries last week, ending its brief stint on the New York Stock Exchange. The transaction places the company under private‑equity stewardship, giving it greater flexibility to pursue long‑term initiatives without the quarterly reporting pressures of a public market. New CEO Dale Clift, a veteran of Trilogy Home Healthcare and the founder of Nurse on Call, took the helm just days after the deal closed, signaling a swift leadership transition aimed at accelerating growth.

Clift’s roadmap centers on double‑digit revenue expansion, with a pronounced emphasis on hospice services. While Enhabit already generates roughly $800 million in home‑health revenue, its hospice line accounts for “a couple hundred million” dollars and offers a higher growth ceiling, according to the CEO. To hit the target, the firm plans to sharpen its sales and marketing playbook, add clinical staff, and pursue opportunistic acquisitions that bolster hospice capacity. The strategy must also navigate industry‑wide headwinds such as staffing shortages and potential Medicare policy shifts that could affect reimbursement rates.

For investors and competitors, Enhabit’s aggressive plan underscores a broader trend of consolidation in post‑acute care, where private‑equity firms seek scale to negotiate better payer contracts and invest in technology‑driven care coordination. If the company can sustain double‑digit growth, it may set a benchmark for other regional hospice operators looking to transition from fragmented ownership to integrated platforms. However, success will hinge on Clift’s ability to retain talent, integrate any acquisitions smoothly, and adapt quickly to regulatory changes that could reshape the hospice market.